Status:
UNKNOWN
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot ...
Eligibility Criteria
Inclusion
- The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers
- Age ≥ 18 years old and able to provide written informed consent;
- Have not received any systemic or topical treatment for kidney/liver tumors.
- Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Exclusion
- The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc.
- The subjects is known or suspected of other malignancies.
- There has been another history of malignancy in the past 5 years.
- Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits.
Key Trial Info
Start Date :
October 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2022
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT04113486
Start Date
October 1 2019
End Date
June 30 2022
Last Update
November 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China, 200092